I just listened in to the Stifel presentation. CEO presented today. It was a very good presentation regarding the lawsuit and PA. I wish he would have spent more time talking about how undervalued the stock is at 2.75.
I am more optimistic about PA doing well once it's launched, compared to Vimovo. It seems that some of the headwinds on Vimovo is based on price. PA on the other hand won't be priced so high, about $1 compared to $.60 for buying individually. I've got to think that vast majority of doctors will prescribe PA vs separately. It's a pretty big market potential. I'd say they can achieve $250M per year in revs.
I'm looking forward to the heart conference in Nov for that data and he said top line data on the PA swtudies by Q2. I think the lower amount of immediate release omeprazole rather than an enteric coating is attractive but I thought he previously said that they are now looking into the PPI's affect on the heart similar to PERVACID's affect on PLAVIX